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Abstract
Remodeling of extracellular matrix (ECM), including regulation of proteogly-
cans in skeletal muscle can be important for physiological adaptation to exer-
cise. To investigate the effects of acute and long-term exercise on the
expression of ECM-related genes and proteoglycans in particular, 26 middle-
aged, sedentary men underwent a 12 weeks supervised endurance and strength
training intervention and two acute, 45 min bicycle tests (70% VO2max), one
at baseline and one after 12 weeks of training. Total gene expression in biop-
sies from m. vastus lateralis was measured with deep mRNA sequencing. After
45 min of bicycling approximately 550 gene transcripts were >50% upregu-
lated. Of these, 28 genes (5%) were directly related to ECM. In response to
long-term exercise of 12 weeks 289 genes exhibited enhanced expression
(>50%) and 20% of them were ECM related. Further analyses of proteoglycan
mRNA expression revealed that more than half of the proteoglycans expressed
in muscle were significantly enhanced after 12 weeks intervention. The proteo-
glycan serglycin (SRGN) has not been studied in skeletal muscle and was one
of few proteoglycans that showed increased expression after acute (2.2-fold,
P < 0.001) as well as long-term exercise (1.4-fold, P < 0.001). Cultured, pri-
mary human skeletal muscle cells expressed and secreted SRGN. When the
expression of SRGN was knocked down, the expression and secretion of serpin
E1 (SERPINE1) increased. In conclusion, acute and especially long-term exer-
cise promotes enhanced expression of several ECM components and proteo-
glycans. SRGN is a novel exercise-regulated proteoglycan in skeletal muscle
with a potential role in exercise adaptation.
Introduction
Approximately 640 individual skeletal muscles are found
in the human body, comprising about 40% of body
weight in lean individuals. Physical activity reduces the
risk of numerous chronic diseases including type 2 dia-
betes, cardiovascular diseases, certain types of cancer,
dementia, and sarcopenia (Colberg et al. 2010; American
College of Sports Medicine, 2013). Both a single acute
exercise bout and long-term exercise induce dramatic
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responses in skeletal muscle, including activation of sig-
naling pathways, altered gene expression, metabolic adap-
tation (Egan and Zierath 2013), altered secretory activity
(Trayhurn et al. 2011), and changes in muscle mass and
functionality (Egan and Zierath 2013). These changes also
include regulation and remodeling of the ECM (Kjaer
2004; Gustafsson 2011). The ECM is an important struc-
tural and functional part of muscle, making up a frame-
work for attachment of contracting cells, as well as
playing a role in proliferation, differentiation, migration,
and polarization of cells (Hynes 2009). In skeletal muscle
the ECM is highly structured and critical for force trans-
mission and normal muscle function (Gillies and Lieber
2011; Lund and Cornelison 2013). Many muscle diseases
and aging are associated with alterations in ECM (Serrano
and Munoz-Canoves 2010; Lieber and Ward 2013).
The ECM contains components like collagens, elastin,
glycoproteins, hyaluronic acid, and proteoglycans (Kjaer
2004; Hynes 2009; Gillies and Lieber 2011). Proteoglycans
have been studied in relation to muscle cell differentiation
as well as certain diseases (Brandan and Gutierrez 2013a,
b). The most abundant proteoglycan in skeletal muscle is
decorin (DCN) (Andrade and Brandan 1991; Melo and
Brandan 1993; Velleman et al. 1997) but other proteogly-
cans are also expressed, such as syndecan and glypican
family members found on cell surfaces and perlecan
(HSPG2) found in basement membranes (Brandan and
Gutierrez 2013b). Proteoglycans are located in the ECM
and on cell surfaces where they are important for matrix
assembly, cell attachment and as binding sites for growth
factors. They have important roles in normal tissue
remodeling and in processes leading to accumulation of
ECM in hepatic and lung fibrosis, atherosclerosis, and
diabetic kidney complications (Tabas et al. 2007; Baghy
et al. 2012; Kolset et al. 2012). Proteoglycans are also
located in intracellular secretory compartments (Kolset
et al. 2004). They consist of core proteins covalently
attached to one or several glycosaminoglycan (GAG)
chains. These GAGs are sulfated and negatively charged
and can therefore bind ligands through electrostatic inter-
actions or more specific interactions involving structures
with a defined sulfation pattern (Esko and Selleck 2002;
Gandhi and Mancera 2008; Lindahl and Li 2009).
Norheim et al. (2011) have previously reported that
many proteins secreted from cultured skeletal muscle cells
are related to ECM and that most of them are regulated
by physical activity. Moreover, many proteins are secreted
and deposited in the ECM and involved in ECM turn-
over, including several proteases and protease inhibitors.
The high level of ECM secretory products from muscle
cells suggests that they have important functions in mus-
cle adaptation to physical activity. However, it is surpris-
ing how little is known about the effect of physical
activity on skeletal muscle ECM and proteoglycans. To
our knowledge, no previous study has systematically
investigated the effect of acute and long-term exercise on
regulating skeletal muscle proteoglycans. In this study, we
investigated the effects of acute and long-term exercise on
the mRNA expression of ECM-related genes and proteo-
glycans in human skeletal muscle. Our data show that
skeletal muscle express many proteoglycans and several of
these are upregulated after a 45 min bicycle session and
after 12 weeks of combined strength and endurance
training.
In addition to the classical cell surface, basement mem-
brane, and connective tissue proteoglycans, we report that
SRGN is expressed in human skeletal muscle and is one
of few proteoglycans to be upregulated after acute as well
as long-term exercise. The proteoglycan SRGN has mostly
been studied in hematopoietic cells (Kolset and Pejler
2011; Korpetinou et al. 2014). It consists of a small core
protein (18 kDa) and several GAG chains that are
attached to the central part of the core protein. SRGN is
located in secretory vesicles or granules where it is
involved in regulating storage or secretion of histamine,
serotonin, and some secretory proteins (Abrink et al.
2004; Kolset and Pejler 2011; Korpetinou et al. 2014).
The extracellular functions of SRGN have not been stud-
ied to any great extent. However, it has been observed on
the surface of multiple myeloma cells bound to CD44
(Purushothaman and Toole 2014) and shown to be
involved in cell adhesion (Skliris et al. 2013; Purushotha-
man and Toole 2014), tumor growth and vascularization
(Purushothaman and Toole 2014).
SERPINE1 is an exercise-regulated (Norheim et al.
2011), antifibrinolytic protease inhibitor that inhibits tis-
sue plasminogen activator and urokinase, the two major
activators of plasminogen (Gramling and Church 2010;
Ghosh and Vaughan 2012). The plasminogen activation
system is important for ECM remodeling in skeletal mus-
cle (Serrano and Munoz-Canoves 2010) and has been
related to exercise-induced adaptation and muscle regen-
eration (Hittel et al. 2003; Koh et al. 2005). Furthermore,
SERPINE1 has been implicated in fibrosis (Ghosh and
Vaughan 2012) and identified as an antiangiogenic factor
(Gramling and Church 2010). Here, we report a potential
role for SRGN in the regulation and secretion of
SERPINE1.
Materials and Methods
Human training intervention
A training intervention study was performed as described
elsewhere (Li et al. 2014; Norheim et al. 2014) (Fig. 1).
The study was approved by the National Committee for
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Research Ethics North, Tromsø, Oslo, Norway
(NCT01803568) and adhered to the standards set by the
Declaration of Helsinki. All participants gave written
informed consent.
Sedentary men with less than 1 bout of exercise per
week the previous year and an age of 40–65 years were
recruited. The participants (n = 26) had an average BMI
of 26.2 kg/m2 (min 20.6, max 32.2). They were initially
recruited to a control group (n = 13) with normal glu-
cose metabolism (BMI 25.5  2 kg/m2) and a dysg-
lycemic group (n = 11) with impaired fasting glucose
≥5.6 mmol/L and/or 2 h serum glucose ≥7.8 mmol/L in
an oral glucose tolerance test (BMI 29  2.4 kg/m2). Two
subjects had an intermediate glucose tolerance and did
not fulfill the inclusion criteria of any group. In this
study, we did not investigate group differences and all
analyses were performed with the two groups pooled and
all subjects were included (n = 26).
The participants underwent 12 weeks of supervised
training with two intervals bicycle sessions and two whole-
body strength-training sessions per week. The strength
training sessions included a 10 min aerobic warm-up and
three sets of each of the following exercises: leg press, leg
curl, chest press, cable pull-down, shoulder press, seated
rowing, abdominal crunches, and back extension. The
endurance training sessions included a session of 7 min
intervals at 85% of maximum heart rate and a session of
2 min intervals at >90% of maximum heart rate. The
number of 7 min intervals per session progressed from 3
to 4 after the second week and from 4 to 5 after 6 weeks.
Number of 2 min intervals per session progressed from 6
to 7 after the second week and from 7 to 10 after 6 weeks.
The participants had an attendance rate of 89%.
A 45 min bicycle test at 70% of VO2max was per-
formed both before and after the 12 weeks training
period. Participants refrained from strenuous physical
activity 2 days before the test and had a standard endur-
ance session 3 days before the last bicycle test. The bicycle
tests were preceded and followed by muscle biopsies, adi-
pose tissue biopsies, and blood sampling. Tests before the
12 weeks intervention included euglycemic hyperinsuline-
mic clamp, maximum strength, and body composition
measured by magnetic resonance imaging (MRI)/MR
spectrometry (MRS) (Li et al. 2014). All participants
underwent a full body MRI examination and MRS within
3 weeks prior to the start of the training period and a
new examination within 2 weeks of the final exercise test.
Blood samples and muscle biopsies from m. vastus later-
alis were taken at 6 time points, before, directly after and
2 h after the acute bicycle tests (Fig. 1). Subcutaneous fat
biopsies were collected from the periumbilical region in a
suction-based biopsy procedure at two time points;
30–60 min after the bicycle test, before and after 12 weeks
of training intervention. Blood sampling was performed by
standard antecubital venous puncture. Muscle tissue was
obtained by needle biopsies. The biopsies before and
directly after the bicycle sessions were taken in the same
incision in the distal and proximal direction of m. vastus
lateralis, so that the distance between biopsies was typically
3–8 cm. The biopsies collected after 2 h were taken from a
second incision. Muscle biopsies were immediately rinsed
in ice cold PBS and dissected free of blood vessels and fat
before they were transferred to RNA-later (Qiagen, Hilden,
Germany) over night and frozen at 80°C. Adipose tissue
biopsies were immediately frozen in liquid nitrogen and
stored at 80°C until further processing.
High throughput mRNA sequencing of mRNA
from muscle and adipose tissue biopsies
To isolate mRNA, frozen muscle biopsies were crushed to
powder with a pestle in a liquid nitrogen-cooled mortar.
Muscle tissue powder and frozen adipose tissue biopsy
pieces were homogenized using TissueRuptor (Qiagen) at
Figure 1. Design of the MyoGlu intervention study. Twenty-six middle-aged, sedentary men underwent a 12 weeks supervised training
intervention. Before and after the intervention the participants undertook a 45 min acute bicycle test (70% VO2max). Muscle biopsies and
blood samples were harvested before (Pre), immediately after (00) and 2 h after the end of the bicycle sessions (2 h). Adipose tissue biopsies
were collected 30–60 min after the two bicycle tests. To study the effect of an acute exercise bout, the main comparison made was between
the samples taken before and immediately after 45 min bicycling at baseline of the study, indicated with the short dashed arrow. The effect of
45 min bicycling after the 12 weeks intervention was also investigated and the results were similar to the baseline data. To study the effect of
long-term training the samples harvested before the acute tests at baseline and after 12 weeks were compared, indicated by the long dashed
arrow.
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full speed, twice for 15 sec in 1 mL QIAzol Lysis Reagent
(Qiagen) and then total RNA was isolated using
miRNeasy Mini Kit (Qiagen) for muscle samples or
RNeasy Lipid Tissue Mini Kit (Qiagen) for adipose tissue
samples. RNA integrity and concentration were determined
using Agilent RNA 6000 Nano Chips on a Bioanalyzer 2100
(Agilent Technologies Inc, Waldbronn, Germany).
RNA from fat (200 ng) and muscle (500 ng) was
reverse-transcribed into cDNA on a Gene Amp PCR 9700
thermal cycler with the high capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA). The
cDNA reaction mixture was diluted in water and an
equivalent of 12.5 ng RNA was analyzed in each sample.
The cDNA samples generated from biopsies were deep-
sequenced using the Illumina HiSeq 2000 system with
multiplexed design (Norheim et al. 2014). The cDNA was
sonically fragmented and size selected to 51 base pair long
reads before amplification. On average the library size was
44.1 million single end reads with no difference between
groups or time points. Read alignment was done against
the UCSC hg19 annotated transcriptome and genome
dated 14 May 2013. Tophat 2.0.8 with Bowtie 2.1.0 was
used with default settings and allowing two mismatches
per uniquely aligned read (Langmead et al. 2009; Kim
et al. 2013). Aligned reads at any genomic location were
visually inspected using the Integrative Genomics Viewer
(Robinson et al. 2011).
EdgeR v3.4.2 (Robinson et al. 2010) was used for gene
filtering strategies, normalization and testing for statistical
significance (P-values) using a negative binominal gener-
alized linear model in R v3.0.3 (The R Foundation,
Vienna, Austria) following the edgeR developers’ instruc-
tions. Normalized gene expression levels are presented in
Fragments Per Kilobase of transcript per Million mapped
reads (FPKM). Correction for multiple testing (q-values)
was performed using Benjamini–Hochbergs false discov-
ery rate (FDR) control (Benjamini and Hochberg 1995),
set at FDR < 10%.
Genes encoding ECM-related proteins were identified
by using the MatrisomeDB (http://matrisomepro-
ject.mit.edu/) developed by the Matrisome project (Naba
et al. 2012). Genes encoding collagens, ECM glycopro-
teins, proteoglycans, ECM regulators, and affiliated pro-
teins were included. Other secreted factors including
growth factors were not included.
Immunohistochemistry on muscle biopsies
Human muscle biopsies were fixed in 4% paraformalde-
hyde (w/v), 0.025% glutaraldehyde (v/v) in PBS for 4–6 h
at room temperature. The biopsies were stored in a 1:10
dilution of the fixative at 4°C until paraffin embedding
and then cut into 5 lm sections using a rotary micro-
tome (HM 355 S; MICROM International GmbH, Wall-
dorf, Germany) and mounted on Superfrost Plus glass
slides (Thermo Scientific, Braunschweig, Germany). The
sections were incubated at 37°C overnight and deparaf-
finized in xylene (Sigma-Aldrich, St Louis, MO) twice for
5 min. Then the sections were rehydrated stepwise in
100%, 96%, 70%, and 50% ethanol for 5 min each and
rinsed in tap water for 5 min. Heat-induced antigen
retrieval was done by heating in 1 mmol/L EDTA (pH 8)
at 95°C for 15 min and cooling to room temperature for
20 min. Next, the muscle sections were incubated for 1 h
in blocking solution 1 (PBS containing 0.05% Triton
X-100, 1% BSA and 3% newborn calf serum) at room
temperature, followed by overnight incubation at 4°C with
primary antibody (anti-human SRGN, 1 lg/mL, a kind
gift from Professor Niels Borregaard, Rigshospitalet,
Copenhagen, Denmark) diluted in blocking solution 2
(PBS containing 0.05% Triton X-100, 1% BSA and 10%
newborn calf serum). Sections were incubated with fluo-
rochrome-conjugated secondary antibodies (Alexa Flour
488, 5 lg/mL; Invitrogen, Eugene, OR) in blocking solu-
tion 2. The slides were dried and mounted with ProLong
Gold with DAPI (Invitrogen).
Images were obtained with an Olympus BX61 upright
fluorescent microscope (Olympus, Tokyo, Japan) and a
Zeiss LSM510 camera (Zeiss, Oberkochen, Germany)
through a 409 or 639 oil objective lens, equipped with
argon (488 nm), HeNe1 (543 nm) and diode (405) lasers.
Pinhole was kept at 1 AU. The fluorochromes were
excited sequentially.
Cell culture studies
Cell culturing and electric pulse stimulation
Primary human myoblasts from either m. obliquus inter-
nus abdominis or m. vastus lateralis of five healthy, male
donors (33–53 years of age) were isolated as previously
described (Haugen et al. 2010). Myoblasts at passage 4 to
5 were proliferated in dishes coated with collagen type I
from rat tail (Sigma-Aldrich), in DMEM/Ham’s F12
1:1 (Gibco, Life Technologies, Grand Island, NY;
Sigma-Aldrich) containing GlutaMAXTM (Gibco, Life
Technologies, Paisley, UK), 50 U/mL penicillin, 50 lg/mL
streptomycin, 5 mmol/L glucose, 10% fetal bovine serum,
1 nmol/L insulin, 10 ng/mL epidermal growth factor,
2 ng/mL basic fibroblast growth factor and 0.4 lg/mL
dexamethasone (Sigma-Aldrich). When the cultures were
80% confluent, the myoblasts were differentiated for
5 days to multinucleated myotubes by changing the med-
ium to DMEM/Ham’s F12 1:1 (5 mmol/L glucose) con-
taining GlutaMAXTM, 50 U/mL penicillin, 50 lg/mL
streptomycin and 2% horse serum (Sigma-Aldrich). Some
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cell cultures were incubated with 1 lg/mL lipopolysaccha-
ride (LPS), 1 lg/mL brefeldin A, 0–2 lmol/L ionomycin
or 1 lmol/L forskolin (Sigma-Aldrich). After 5 days of
differentiation the cultures were subjected to electric pulse
stimulation (EPS) with a frequency of 1 Hz, pulse dura-
tion 2 ms and an intensity of 11.5 V for 24 h. EPS was
applied in serum-free conditions with a C-Dish in combi-
nation with a C-Pace pulse generator (C-Pace 100;
IonOptix, Milton, MA).
Serglycin gene silencing
To investigate whether silencing of SRGN mRNA expres-
sion can influence myoblast proliferation, human myoblast
cultures of 50% confluence were incubated for 24 h with
10 nmol/L SRGN siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA) or scramble siRNA (Qiagen) and 8 lL/mL
HiPerfect Transfection Reagent (Qiagen) in normal prolif-
eration medium. After another 48 h cell numbers were
counted with a CountessTM automated cell counter (Invitro-
gen) and protein concentrations were measured with a
PierceTM BCA Protein Assay Kit (Thermo Scientific, Rock-
ford, IL). The effect of SRGN silencing on the mRNA
expression and secretion of SERPINE1 was investigated in
myotubes. The muscle cell cultures were differentiated for
1 day and then incubated with 10 nmol/L SRGN siRNA or
scramble siRNA and 16 lL/mL HiPerfect Transfection
Reagent in medium containing 2% horse serum for 24 h.
After another 48 h the cells were incubated with serum-free
medium for 24 h and the concentration of SERPINE1 in
the conditioned medium was measured with a Quantikine
ELISA Kit (RnD Systems, McKinley Place NE, MN). The
silencing efficacy was quantified by reverse transcription
polymerase chain reaction after 24, 48 and 96 h and
untreated controls and controls incubated with only HiPer-
fect reagent were included.
Reverse transcription polymerase chain reaction
Total RNA was isolated from cell cultures with the
RNeasy Mini kit (Qiagen) according to the manufac-
turer’s protocol. RNA (550 ng) was reverse-transcribed
into cDNA as described under the section on high
throughput mRNA sequencing.
Predeveloped primers and probe sets (TaqMan assays;
Applied Biosystems) were used to analyze mRNA levels of:
large ribosomal protein P0 (RPLP0, Hs99999902_m1),
myogenin (MYOG, Hs01072232_m1), myosin heavy
chain 7 (MYH7, Hs01110632_m1), interleukin 6 (IL6,
Hs00985639_m1), peroxisome proliferator-activated recep-
tor gamma, coactivator 1 alpha (PPARGC1A, Hs01016719_
m1) and SRGN (Hs01004159_m1). Relative target mRNA
expression levels were calculated as 2[Ct(target)Ct(RPLP0)].
Metabolic labeling of (35S)macromolecules
Human myoblasts or myotubes were incubated in
100 lCi/mL (35S)sulfate (Hartmann Analytic GmbH,
Braunschweig, Germany) in standard medium for 24 h.
Conditioned media were collected and centrifuged to
remove cell debris and the cell fractions were lysed in
Hepes buffer (pH 7.4) with 1% Triton X-100. To remove
unincorporated (35S)sulfate and to recover (35S)sulfated
macromolecules, medium and cell lysates were subjected
to SephadexTM G-50 Fine (GE Healthcare, Little Chalfont,
UK) gel chromatography (Meen et al. 2011). The sulfated
macromolecules were eluted in the void volume with
0.05 mol/L Tris–HCl, 0.05 mol/L NaCl, pH 8. The
amount of (35S)macromolecules isolated was quantified
by scintillation counting. Samples were concentrated
using Amicon Ultra centrifugal tubes with a molecular
mass cut off at 3 kDa and the protein concentrations
were determined using the PierceTM BCA Protein Assay
Kit (Thermo Scientific).
SDS-PAGE
(35S)Macromolecules from cell and medium fractions were
analyzed with SDS-PAGE. To degrade (35S)proteoglycans
with (35S)chondroitin and dermatan sulfate chains, samples
were incubated with 0.01 units of chondroitinase ABC
(cABC; AMS Biotechnology, Abingdon, UK) in 0.05 mol/L
Tris–HCl pH 8.0 containing 0.05 mol/L sodium acetate
and 0.02% BSA for 37°C overnight. A unique feature of the
proteoglycan SRGN is the resistance to degradation by
trypsin (Stevens et al. 1985). To analyze the possible pres-
ence of trypsin-resistant (35S)proteoglycans in muscle cells
cultures, samples were incubated with 0.08% trypsin-EDTA
at 37°C overnight. Soybean trypsin inhibitor (Sigma-
Aldrich, 0.625%, final concentration) was added the next
day. For comparison on SDS-PAGE each sample contained
the same amount of (35S)sulfate (18 000 mCi/well). To
control for trypsin activity, dual color molecular weight
standard was incubated with the same amount of trypsin-
EDTA and trypsin inhibitor solutions. After SDS-PAGE,
the 4–20% CriterionTM Precast gels (Bio-Rad, Hercules,
CA) were incubated in fixative (isopropanol 25%, glacial
acetic acid 10%) for 30 min and thereafter in Amersham
Amplify Fluorographic Reagent (GE Healthcare) for
15 min. Dried gels were subjected to fluorography using
Amersham HyperfilmTM ECL (GE Healthcare) for approxi-
mately 4–5 days at 20°C.
Immunoprecipitation
Isolated (35S)macromolecules from media and cell frac-
tions of myoblasts and myotubes incubated with or
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without LPS were subjected to SephadexTM G-50 gel filtra-
tion. Samples containing equal amounts of protein were
incubated with or without cABC or trypsin-EDTA (de-
scribed above). Then the samples were incubated with
0.65 lg/mL rabbit anti-human SRGN antibody (a kind gift
from Professor Niels Borregaard, Rigshospitalet, Copen-
hagen, Denmark) overnight at 4°C and then with 30 lg
Dynabeads Protein G (Invitrogen) for 1 h at 4°C. After
three washing steps in buffer (0.05 mol/L Tris-HCl,
0.15 mol/L NaCl, 0.05% Triton X-100) followed by boiling
for 5 min in Laemmli sample buffer, all samples were
loaded on to a 4–20% SDS-PAGE gel, incubated in fixative
and Amplify Fluorographic Reagent (GE Healthcare), dried
and subjected to fluorography for 4–5 weeks at 20°C.
Immunohistochemistry of cultured muscle cells
Human muscle cells were cultured on glass slides coated
with collagen type I from rat tail (Sigma-Aldrich), fixed
in 4% paraformaldehyde for 10 min and washed in PBS
and water. The fixed cells were incubated with affinity
purified rabbit anti-human SRGN (1 lg/mL) and mono-
clonal mouse anti-human desmin (10 lg/mL; Abcam,
Cambridge, UK), in PBS with 1.25% BSA and 0.2% sapo-
nin, overnight at 4°C. The cells were washed and incu-
bated with relevant secondary antibodies (Alexa Flour 488
and 594 anti-IgG, 5 lg/mL; Invitrogen) for 90 min at
room temperature and washed in PBS and water. The
slides were dried and mounted with ProLong Gold with
DAPI (Invitrogen). Images were obtained with an Olym-
pus BX61 as described for the muscle biopsies.
Statistical analysis
Statistical analysis of in vitro data was performed using
SPSS 20.0 software (IBM Corporation, Armonk, NY) and
Microsoft Excel 2010. Effect measures are presented as
mean  standard error of the mean. To test for differ-
ences between conditions or time points we used ANOVA
and/or Student’s t-test.
Results
ECM-related genes are regulated by acute
exercise in skeletal muscle
We used global mRNA sequencing to monitor the total
mRNA expression in biopsies from m. vastus lateralis
from 26 men. Immediately after a 45 min bicycle session
at baseline of the 12 weeks training intervention (Fig. 1),
about 550 gene transcripts were significantly and more
than 50% upregulated (FDR < 0.05). Of these, 28 genes
(5%) encoded structural or regulatory components of the
ECM (Table 1). Many of the genes with increased expres-
sion after acute exercise were proteases or protease-in-
hibitors involved in turnover of ECM. Six genes in the
serine protease inhibitor family (serpins) were upregu-
lated. The metallopeptidase ADAMTS4 was by far the
most upregulated ECM-related gene (18.9-fold). The pro-
teoglycan syndecan 4 (SDC4) had a high expression level
(16.5 FPKM) and increased 1.9-fold during the acute
bicycle session. Matricellular proteins are components of
the ECM with a regulatory role. CTGF is encoding a
matricellular protein that is an important growth factor
regulating ECM biosynthesis (Kubota and Takigawa 2015)
and was expressed at relatively high levels in the muscle
biopsies (6.6 FPKM). Several members of the semaphorin
(SEMA) family showed enhanced mRNA expression.
These proteins are either secreted or membrane-bound
and are related to several cellular functions such as cell
adhesion, communication, and migration (Worzfeld and
Offermanns 2014). A total of five ECM genes were more
than 1.5 times downregulated, demonstrating that far
fewer genes were downregulated than upregulated.
Because proteoglycans are important constituents of
ECM and have not been systematically investigated in
response to training, we decided to investigate a broad
specter of them in further detail. Of the 39 investigated
proteoglycans, 23 were consistently expressed in skeletal
muscle and several were increased after acute exercise
(Table 2). The highest expression level was found for
DCN (111 FPKM). High expression levels were also
observed for the cell surface proteoglycans glypican-1
(GPC1) and SDC4. A novel finding in this study was the
demonstration of SRGN expression in muscle biopsies
(7.8 FPKM), which also had the highest induction after
45 min bicycling, both before (2.2-fold) and after
12 weeks of training intervention (1.9-fold; Fig. 2A).
Before the intervention all 26 participants showed an
acute increase in SRGN mRNA (range 1.3–3.9-fold). Fur-
thermore, SDC4 mRNA was increased 1.9-fold (Table 2)
and CD44 and chondroitin sulfate proteoglycan 4
(CSPG4) were also significantly upregulated immediately
after the 45 min acute work-load. In contrast, asporin
(ASPN), agrin (AGRN), and leprecan (LEPRE1) mRNA
levels were significantly reduced.
ECM genes are regulated by long-term
exercise
The skeletal muscle was affected by 12 weeks of combined
endurance and strength training; thigh muscle area (mea-
sured by MRI) increased 7.5% (P < 0.001), and muscle
strength (measured by a maximum leg press test)
increased 9.6% (P < 0.001) (Table 3). A substantially lar-
ger number of ECM-related transcripts were enhanced
2015 | Vol. 3 | Iss. 8 | e12473
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during 12 weeks of training than after acute exercise. In
total, 280 genes were significantly upregulated more than
50% (FDR < 0.05) in m. vastus lateralis after the long-
term exercise and 20% of these were related to ECM
(Table 4). The matricellular protein secreted protein
acidic and rich in cysteine (SPARC) had the highest
expression level (71.5 FPKM) of all the upregulated,
ECM-related genes and increased 76% during 12 weeks of
training. Matrix-remodeling-associated protein 5
(MXRA5) had the highest relative increase of 2.8-fold
although the absolute expression level was low
(0.5 FPKM). Many mRNAs of structural ECM compo-
nents were enhanced, including 10 collagens (COL), elas-
tin (ELN), laminins (LAMA4, LAMB1, LAMC3), and
nidogen 1 and 2 (NID1, NID2). Five members of the
ADAMTS family and two SERPINs were also upregulated.
Only two ECM-related genes were more than 1.5-fold
downregulated; laminin beta 3 (LAMB3; FC = 1.56,
P < 0.001) and chondroadherin (CHAD; FC = 1.52,
P < 0.001).
More than half of all the expressed proteoglycans were
significantly increased after the 12 weeks training and six
were upregulated more than 50% (Table 5). Interestingly,
the basement membrane proteoglycans HSPG2, AGRN,
and COL18A1 were all upregulated. Many of the small
leucine-rich proteoglycans were also increased, including
biglycan (BGN), osteoglycin (OGN), ASPN and lumican
Table 1. Extracellular matrix (ECM) related genes upregulated by
acute exercise. Gene transcripts related to ECM that were more
than 50% upregulated after an acute 45 min exercise session in
m. vastus lateralis
Gene symbol FPKM* Fold change† P-value q-value‡
ADAMTS4 0.4 18.9 6E-67 3E-64
THBS1 0.4 8.6 2E-22 6E-21
CYR61 9.3 8.0 8E-40 9E-38
ADAMTS1 5.9 7.2 1E-85 1E-82
SERPINE1 0.8 4.8 1E-27 5E-26
PLAU 2.6 3.6 7E-21 2E-19
TNFAIP6 0.5 3.2 3E-14 7E-13
CTGF 6.6 3.1 1E-27 6E-26
SERPINH1 6.7 3.0 1E-43 2E-41
SEMA4C 3.1 2.7 1E-80 1E-77
MMP19 0.3 2.2 3E-06 2E-05
SRGN 7.8 2.2 4E-53 1E-50
SERPINB9 0.8 2.2 2E-26 1E-24
SERPINA1 0.2 1.9 4E-06 3E-05
SDC4 16.5 1.9 1E-28 8E-27
SEMA3F 2.0 1.9 4E-45 6E-43
SEMA6B 1.6 1.9 1E-34 1E-32
CRISPLD2 3.3 1.8 4E-25 2E-23
HAPLN3 0.9 1.8 2E-11 2E-10
SERPINB8 0.3 1.8 3E-16 8E-15
SERPINA3 0.5 1.7 5E-05 3E-04
SEMA7A 0.6 1.7 5E-17 1E-15
CLEC1A 1.0 1.7 5E-08 5E-07
TNC 0.4 1.6 2E-05 1E-04
VWA1 1.5 1.6 5E-21 2E-19
ADAM8 0.3 1.5 3E-06 2E-05
TIMP1 6.8 1.5 1E-10 2E-09
POSTN 0.5 1.5 4E-04 2E-03
*Gene expression level at baseline measured by mRNA sequenc-
ing, expressed as Fragments Per Kilobase of transcript per Million
mapped reads (FPKM).
†The expression just after 45 min bicycling as compared to before,
at baseline of the 12 weeks intervention.
‡False discovery rate.
Table 2. Proteoglycans expressed in m. vastus lateralis and the
mRNA regulation after an acute exercise session
Gene
Gene
symbol FPKM*
Fold
change† P-value q-value‡
Serglycin SRGN 7.8 2.2 4E-53 1E-50
Syndecan 4 SDC4 16.5 1.9 1E-28 8E-27
CD44 antigen CD44 1.8 1.2 3E-10 3E-09
Chondroitin
sulfate
proteoglycan 4
CSPG4 2.6 1.2 2E-04 9E-04
Versican VCAN 0.6 1.1 1E-02 4E-02
Syndecan 2 SDC2 4.6 1.1 1E-01 2E-01
Decorin DCN 110.9 1.1 2E-01 3E-01
Biglycan BGN 2.9 1.1 5E-01 6E-01
Syndecan 3 SDC3 2.6 1.0 4E-01 5E-01
Glypican 1 GPC1 43.8 1.0 6E-01 7E-01
Lumican LUM 10.0 1.0 9E-01 9E-01
Perlecan HSPG2 12.4 1.0 9E-01 9E-01
Collagen, type
XVIII, alpha 1
COL18A1 5.8 1.0 9E-01 9E-01
Testican 2 SPOCK2 1.7 1.0 3E-01 5E-01
Podocan-like 1 PODNL1 0.5 0.9 4E-01 5E-01
Osteoglycin OGN 0.6 0.9 7E-01 8E-01
Podocan PODN 5.6 0.9 1E-01 2E-01
Testican 1 SPOCK1 1.9 0.9 2E-01 3E-01
Glypican 4 GPC4 8.2 0.9 3E-05 2E-04
Agrin AGRN 1.9 0.8 2E-05 1E-04
Glypican 3 GPC3 0.5 0.8 1E-01 3E-01
Asporin ASPN 2.5 0.8 6E-08 5E-07
Leprecan LEPRE1 1.9 0.7 5E-05 3E-04
Sixteen other proteoglycans were included in the analysis, but
were not expressed in skeletal muscle above the threshold: ACAN,
BCAN, CSPG5, EPYC, GPC2, GPC5, GPC6, IMPG1, IMPG2, KERA,
NCAN, NYX, OPTC, PRG2, PRG3, and SDC1.
*Gene expression level at baseline measured by mRNA sequenc-
ing, expressed as Fragments Per Kilobase of transcript per Million
mapped reads (FPKM).
†The expression after 45 min bicycling as compared to before, at
baseline of the 12 weeks intervention.
‡False discovery rate.
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(LUM). Glypican 4 (GPC4) was the only proteoglycan to
be significantly downregulated.
SRGN, CD44, CSPG4, and versican (VCAN) were all
increased by acute as well as long-term exercise and
SRGN was the proteoglycan with the highest expression
level of these. SRGN mRNA expression increased 40%
during 12 weeks of training and an increase could be
demonstrated in 24 of the 26 participants.
Biopsies from subcutaneous adipose tissue were also har-
vested before and after 12 weeks of training. In contrast to
the skeletal muscle, total body fat measured by MRI was
reduced 8.2% (P < 0.001). We observed a much smaller
response to 12 weeks of training on gene expression levels
in adipose tissue than in skeletal muscle. ADAMTS4 was
the only ECM-related gene upregulated more than 50%,
whereas only collagen XXIIa1 (COL22A1) was more than
1.5-fold decreased (1.86-fold, P = 0.007). SRGN was
expressed at high levels in adipose tissue, but the expression
was unaffected by long-term exercise (Fig. 2B).
Intracellular localization of serglycin
We chose to focus on SRGN in further studies because
SRGN was one of few proteoglycans regulated by acute as
well as long-term physical activity and it was expressed at
a fairly high level and has previously not been studied in
skeletal muscle. To evaluate the presence of SRGN in
muscle tissue, biopsies from m. vastus lateralis were ana-
lyzed by immunostaining. SRGN was identified in the
perinuclear region of muscle fibers (Fig. 3).
The presence of SRGN was also investigated in cul-
tured, primary human muscle cells; both myoblasts
(mononuclear cells) and myotubes (myoblasts that have
fused and differentiated into multinuclear cells) were
immunostained. SRGN was located in cytoplasmic vesicles
and enriched in the perinuclear region of myoblasts. A
much higher level of SRGN was detected in myoblasts
(Fig. 4A) as compared to myotubes (Fig. 4E). In the dif-
ferentiated cultures most cells were myotubes, although a
few mononuclear cells were still present and these exhib-
ited a higher SRGN signal as indicated by arrows in
Figure 4E and F. These data indicate that SRGN is pre-
dominantly expressed in myoblasts in vitro.
In vitro expression and secretion of
serglycin
To further evaluate the expression of SRGN in myoblasts
and myotubes, the mRNA expression in differentiating
muscle cell cultures was measured. During 8 days of dif-
ferentiation the cells fused into multinuclear myotubes
and the expression of myogenic genes such as MYOG and
MYH7 increased. The peak induction of MYOG was 10–
36-fold and MYH7 18–623-fold, depending on cell donor
(Fig. 5A and B). In agreement with the immunocyto-
chemistry data, the expression of SRGN gradually
decreased during differentiation and was reduced 79%
after 5 days (Fig. 5C).
To study de novo synthesis and secretion of proteogly-
cans, primary human myoblasts were incubated with
(35S)sulfate for 24 h. Radiolabeled sulfate is incorporated
into the GAG chains of proteoglycans during biosynthesis.
Cell and medium fractions were analyzed by SDS-PAGE
and fluorography. SRGN consists of a small core protein
with several GAG chains. Because SRGN and other pro-
teoglycans have varying amounts of GAG chains they
appear as broad bands after electrophoresis. Conditioned
medium contained several (35S)proteoglycans. The major
part was of molecular weight above 250 kDa (Fig. 5D).
Most of the radiolabeled material was susceptible to incu-
A B
Figure 2. Serglycin mRNA is upregulated in m. vastus lateralis after
acute and long-term training. Expression of SRGN mRNA in: (A)
muscle biopsies collected before (Pre); immediately after 45 min
ergometer cycling (70% VO2max) (0
0); and after 2 h rest (2 h);
before and after 12 weeks of training; (B) adipose tissue before
and after long-term training. Data are expressed as FPKM. Bars
depict means  SEM. **P < 0.01, ***P < 0.001.
Table 3. Characteristics of participants (n = 26) before and after
12 weeks training
Baseline 12 weeks Change (%)
Age (years) 51.2 (6.6)
BMI (kg/m2) 26.3 (3.5) 26.1 (3.3) 0.7 (3.4)
Thigh muscle area (cm2) 214 (55) 231 (56) 7.5 (4.8)*
Fat mass (L) 38.7 (9.5) 35.7 (8.4) 8.2 (6.0)*
GIR (mg/kg/min) 5.9 (2.4) 7.9 (3.3) 23.5 (20.0)*
Leg strength (kg) 224 (41) 248 (45) 9.6 (6.4)*
VO2max (mL/kg/min) 40.6 (5.8) 45.8 (6.4) 11.2 (7.4)*
Values are mean (SD).
*Significant change after 12 weeks.
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bation with cABC (lane 2). cABC is an enzyme that only
degrades GAG chains of the chondroitin (CS)/dermatan
sulfate (DS) type. Hence, the major part of proteoglycans
secreted from cultured primary muscle cells were CS/DS-
proteoglycans. SRGN has been shown to be trypsin-resis-
tant, because the core protein is protected by the densely
packed GAG chains (Stevens et al. 1985). We made use
of this criterion to investigate if human muscle express
and secrete a trypsin-resistant proteoglycan. In lane 3 in
Figure 5D it is shown that a trypsin-resistant (35S)proteo-
glycan with molecular weight >250 kDa was present in
the medium. The cell fractions were subjected to the same
analyses and limited amounts of (35S)proteoglycan mate-
rial were detected, supporting the notion that proteogly-
cans are mainly secretory products in cultured human
muscle cells.
The trypsin-resistant band is likely to be SRGN. To
investigate this further, conditioned medium from radio-
labeled cells was subjected to immunoprecipitation with a
SRGN antibody, followed by SDS-PAGE and fluorography
(Fig. 5E). A proteoglycan with a migration pattern similar
to that observed for the trypsin-resistant band in Fig-
ure 5D was recovered after immunoprecipitation. This
band was also trypsin-resistant. In addition, after cABC
incubation two core proteins with molecular weights of
approximately 20 and 25 kDa appeared, most likely rep-
resenting SRGN core proteins with different amounts of
(35S)GAG stubs left after incubation with cABC. Two core
proteins (20 and 35 kDa) appearing after cABC incuba-
tion of SRGN has also been demonstrated in monocytes
(Kolset and Zernichow 2008). Our data confirm that pri-
mary human myoblasts secrete SRGN.
The amount of intracellular SRGN increased in myo-
blasts and myotubes incubated with brefeldin A. Brefeldin
A is an inhibitor of the classical secretory pathway pro-
Table 4. Extracellular matrix (ECM)-related genes upregulated by
12 weeks of training. Gene transcripts related to the ECM that
were more than 50% upregulated in m. vastus lateralis after
12 weeks of exercise
Gene symbol FPKM* Fold change† P-value q-value‡
MXRA5 0.5 2.8 4E-16 3E-14
COL1A1 4.9 2.4 5E-20 8E-18
COL3A1 16.7 2.4 3E-19 4E-17
COL4A1 14.1 2.4 2E-29 2E-26
THBS4 21.7 2.2 5E-22 1E-19
LOXL2 1.1 2.2 5E-27 3E-24
COL4A2 13.4 2.2 6E-28 4E-25
BGN 2.9 2.1 2E-17 2E-15
OGN 0.6 2.1 4E-08 6E-07
COL6A6 0.1 2.0 2E-08 3E-07
LOX 0.3 2.0 1E-25 4E-23
PXDN 3.0 2.0 4E-32 5E-29
WISP1 0.1 1.9 1E-11 3E-10
SEMA5B 0.2 1.9 9E-12 3E-10
ADAMTS7 0.5 1.8 5E-21 9E-19
ASPN 2.5 1.8 1E-17 1E-15
COL14A1 0.6 1.8 3E-11 7E-10
OMD 0.3 1.8 8E-07 8E-06
COLEC12 2.3 1.8 1E-20 2E-18
COL1A2 16.1 1.8 3E-12 1E-10
SPARC 71.5 1.8 1E-26 5E-24
CLEC10A 0.7 1.7 4E-07 4E-06
LAMB1 6.8 1.7 2E-18 3E-16
CTHRC1 1.3 1.7 5E-12 2E-10
PAMR1 0.9 1.7 1E-05 7E-05
LAMA4 3.0 1.7 3E-36 1E-32
NID2 2.3 1.7 9E-25 3E-22
VWA1 1.5 1.7 9E-18 1E-15
LAMC3 0.1 1.7 2E-04 1E-03
KCP 0.2 1.7 6E-09 1E-07
ITIH3 0.5 1.7 1E-05 9E-05
IGFBP3 3.5 1.7 5E-18 5E-16
CLEC7A 0.6 1.6 4E-14 2E-12
AGRN 1.9 1.6 5E-21 9E-19
ADAMTS15 0.8 1.6 1E-22 3E-20
KAZALD1 2.1 1.6 1E-15 7E-14
EMILIN3 0.4 1.6 3E-04 1E-03
COL5A2 2.9 1.6 6E-13 2E-11
PLXNB3 0.1 1.6 1E-05 9E-05
ECM2 1.9 1.6 4E-17 4E-15
THBS1 0.4 1.6 3E-06 2E-05
ADAMTS8 0.3 1.6 3E-04 1E-03
SERPINE1 0.8 1.6 7E-07 7E-06
ADAMTSL3 0.8 1.6 4E-15 2E-13
NID1 4.3 1.6 4E-18 4E-16
ADAMTS2 0.3 1.6 1E-06 1E-05
IGFBP2 4.0 1.6 2E-11 5E-10
SERPINH1 6.7 1.5 3E-20 4E-18
HSPG2 12.4 1.5 1E-21 3E-19
LOXL3 0.4 1.5 7E-08 9E-07
MMP14 2.7 1.5 2E-15 1E-13
(Continued)
Table 4. Continued.
Gene symbol FPKM* Fold change† P-value q-value‡
IGSF10 0.1 1.5 2E-04 8E-04
GREM1 0.7 1.5 8E-08 1E-06
CLEC11A 1.4 1.5 9E-08 1E-06
AEBP1 2.1 1.5 1E-08 2E-07
COL15A1 21.0 1.5 6E-13 2E-11
ELN 2.4 1.5 7E-09 1E-07
COL5A1 2.7 1.5 9E-11 2E-09
LUM 10.0 1.5 2E-06 2E-05
*Gene expression level at baseline measured by mRNA sequenc-
ing, expressed as Fragments Per Kilobase of transcript per Million
mapped reads (FPKM).
†The mRNA expression after 12 weeks of training as compared to
baseline of the intervention.
‡False discovery rate.
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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moting secretory products to accumulate intracellularly
(Kolset et al. 2002). Accumulation of SRGN was observed
in the presence of brefeldin A (Fig. 4C, D, and F), which
is in agreement with the notion that SRGN is a secretory
product. We could detect SRGN in multinuclear myo-
tubes after incubation with brefeldin A, indicating that
SRGN is secreted from myotubes as well as myoblasts.
Regulation of serglycin in muscle cells
To gain more insight in the regulation of SRGN in
human muscle cells, cultured myotubes were subjected to
EPS to stimulate myotube contraction. EPS increased the
expression of the exercise-responsive control genes
PPARGC1A and IL6 as well as SRGN (Fig. 6A). The mus-
cle cells were also incubated with ionomycin and/or for-
skolin to increase cytosolic calcium influx and cAMP
levels. These agents have been shown to induce some of
the changes observed in exercising skeletal muscle (Sparks
et al. 2011). Incubation with ionomycin increased the
expression of PPARGC1A and IL6 (Fig. 6B, C, and E).
Forskolin alone did not influence gene expression, but in
combination with ionomycin, the expression of
PPARGC1A was upregulated 6.1-fold (P = 0.01) and IL6
6.3-fold (P = 0.04; Fig. 6B and C). SRGN expression was
not affected by ionomycin or forskolin (Fig. 6D and E),
suggesting that transcriptional regulation during exercise
is mediated through other pathways than calcium and
cAMP/PKA signaling.
In further studies on the regulation of SRGN, cultured
myoblasts and myotubes were incubated with LPS. LPS is
a ligand for toll-like receptor 4, has been shown to pro-
mote IL6 expression (Frost et al. 2006) and to be a potent
modulator of SRGN expression in other cell types (Reine
et al. 2014; Kolseth et al. 2015). We incubated muscle
cells with LPS, to investigate whether SRGN is regulated
in a similar manner in muscle cells as in other cell types.
Incubation with LPS promoted increased IL6 and SRGN
mRNA in both myoblasts and myotubes (Fig. 6E and F).
The induction of SRGN was highest after 24 h incubation,
with a five-fold increase in myoblasts and 2.5-fold
increase in myotubes. Furthermore, conditioned medium
immunoprecipitated with a SRGN antibody displayed a
stronger trypsin-resistant band after LPS incubation
(Fig. 5E, lane 3 and 6), demonstrating increased secretion
of SRGN. Finally, immunostaining of cultured myoblasts
showed enhanced perinuclear and vesicular staining of
SRGN after incubation with LPS (Fig. 4B). When the cells
were exposed to both LPS and brefeldin A, a very high
staining intensity could be observed (Fig. 4D).
Serglycin is involved in the regulation of
serpin E1
To investigate the functional role of SRGN in skeletal
muscle cells, SRGN expression was knocked down by
transfecting cultured muscle cells with siRNA. This led to
a robust downregulation of SRGN mRNA (Fig. 7A). As in
previous experiments, de novo synthesis of proteoglycans
was determined by (35S)sulfate labeling followed by SDS-
PAGE. A weaker trypsin-resistant band was evident after
incubation with siRNA (Fig. 7B, lane 6). This band corre-
sponds to SRGN (as demonstrated in Fig. 5D and E).
In myoblasts SRGN was knocked down to examine
whether it could influence proliferation rate. After 48 h
Table 5. Proteoglycans expressed in m. vastus lateralis and the
mRNA regulation during long-term training
Gene
Gene
symbol FPKM*
Fold
change† P-value q-value‡
Biglycan BGN 2.9 2.1 2E-17 2E-15
Osteoglycin OGN 0.6 2.1 4E-08 6E-07
Asporin ASPN 2.5 1.8 1E-17 1E-15
Agrin AGRN 1.9 1.6 5E-21 9E-19
Perlecan HSPG2 12.4 1.5 1E-21 3E-19
Lumican LUM 10.0 1.5 2E-06 2E-05
Collagen, type
XVIII, alpha 1
COL18A1 5.8 1.5 2E-09 4E-08
Chondroitin
sulfate
proteoglycan 4
CSPG4 2.6 1.5 2E-08 3E-07
Serglycin SRGN 7.8 1.4 5E-17 4E-15
Syndecan 3 SDC3 2.6 1.4 7E-18 7E-16
CD44 Antigen CD44 1.8 1.3 8E-10 2E-08
Glypican 3 GPC3 0.5 1.3 1E-01 2E-01
Testican 1 SPOCK1 1.9 1.3 1E-04 7E-04
Versican VCAN 0.6 1.2 4E-02 9E-02
Leprecan LEPRE1 1.9 1.1 6E-04 3E-03
Testican 2 SPOCK2 1.7 1.1 9E-03 3E-02
Decorin DCN 110.9 1.0 6E-01 7E-01
Syndecan 2 SDC2 4.6 1.0 1E+00 1E+00
Podocan PODN 5.6 0.9 4E-01 5E-01
Glypican 1 GPC1 43.8 0.9 1E-01 2E-01
Syndecan 4 SDC4 16.5 0.9 1E-01 2E-01
Podocan-like 1 PODNL1 0.5 0.9 2E-01 3E-01
Glypican 4 GPC4 8.2 0.8 1E-03 5E-03
Testican 3 SPOCK3 0.2 0.7 2E-01 3E-01
Sixteen other proteoglycans were included in the analysis, but
were not expressed over the threshold: ACAN, BCAN, CSPG5,
EPYC, GPC2, GPC5, GPC6, IMPG1, IMPG2, KERA, NCAN, NYX,
OPTC, PRG2, PRG3, SDC1.
*Gene expression level at baseline measured by mRNA sequencing
and expressed as Fragments Per Kilobase of transcript per Million
mapped reads (FPKM).
†The mRNA expression after 12 weeks of training as compared to
baseline of the intervention.
‡False discovery rate.
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A C E
B D F
Figure 4. Perinuclear localization of serglycin in cultured muscle cells. Immunostaining of fixed cultured human muscle cells with antibodies
against SRGN (green) and desmin (red) and DAPI nuclear stain (blue). Primary human myoblasts were incubated with: (A) vehicle, (B) LPS; (C)
brefeldin A; or (D) both for 24 h. Primary human muscle cells were differentiated into multinuclear myotubes and incubated with: (E) vehicle or
(F) brefeldin A for 24 h. Arrows indicate mononuclear cells. Scale bar represents 20 lm in A–D and 32 lm in E–F. The experiments were
performed three times, with two different donors.
A B
Figure 3. Intracellular localization of serglycin in human skeletal muscle. Fixed muscle sections from human m. vastus lateralis were stained
with an antibody against SRGN (green) and DAPI nuclear stain (blue). (A) Cross section; (B) longitudinal section. SRGN-positive perinuclear
staining is indicated by arrows. Scale bar represents 20 lm. Staining was done on biopsies from six different donors taken at a single time
point.
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there was no change in the cell number or protein con-
centration in cultures incubated with siRNA as compared
to controls (Fig. 7C–D).
SERPINE1 is a serine protease inhibitor and is a pre-
dicted functional partner of SRGN in the STRING database
(Korpetinou et al. 2014; Szklarczyk et al. 2015). SERPINE1
was one of the ECM-related genes that were upregulated on
the mRNA level in skeletal muscle after both 45 min bicy-
cling (4.8-fold, P < 0.001) and long-term training (1.6-
fold, P < 0.001; Fig. 7E). Interestingly, SRGN knockdown
in differentiated muscle cells (>75%; Fig. 7A) promoted a
simultaneous increase in SERPINE1 mRNA (Fig. 7F) and
SERPINE1 secretion (Fig. 7G). After 48 h the secretion of
SERPINE1 increased 60% (P = 0.048).
A B
D E
C
Figure 5. Serglycin is expressed and secreted from cultured human myoblasts. (A–C) Human myoblasts were differentiated to multinucleated
myotubes for 8 days and mRNA was harvested every day during the differentiation. The mRNA expression of MYOG, MYH7 and SRGN was
determined by RT-PCR. Gene expression data are relative to the expression of RPLP0 and the expression on day 0 and expressed as means of
fold change. Error bars represent SEM. *P < 0.05, **P < 0.01, **P < 0.001, significant change from day 0. Experiments were performed with
cells from three different donors. (D–E) Primary human myoblasts were incubated with (35S)sulfate for 24 h. (D) Conditioned medium (lane 1–3)
and cell lysates (lane 4–6) were examined with SDS-PAGE and autoradiography. The samples were incubated with or without trypsin (T; lane 3
and 6) or cABC (lane 2 and 5). (E) Conditioned medium from human myoblasts incubated with (35S)sulfate and with or without 1 lg/mL LPS
(lane 1–6) for 24 h. SRGN was immunoprecipitated with anti-human SRGN antibody. IgG controls were included (lane 7–9). The samples were
incubated with or without trypsin (T; lane 3, 6, 9) or cABC (lane 2, 5, 8). The experiment was performed three times, with two different
donors.
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Discussion
In this study, we demonstrate that many genes associated
with ECM are regulated by acute as well as long-term
exercise. After a 45 min exercise session 5% of all genes
upregulated more than 1.5-fold were ECM related; many
of these were proteases and protease inhibitors involved
in turnover of ECM. After 12 weeks of combined endur-
A B
D EC
GF
Figure 6. Electric pulse stimulation (EPS) and lipopolysaccharide (LPS) increases mRNA expression of serglycin. Differentiated human muscle
cells were subjected to EPS (A) or incubated with: (B) 1 lmol/L ionomycin for 3, 6, and 24 h; or (C–E) ionomycin (0–2 lmol/L); forskolin
(f; 1 lmol/L); or both (f + i) for 3 h. (F–G) Human cultured myoblasts or myotubes differentiated for 5 days were incubated with 1 lg/mL LPS
for 3, 6, and 24 h. The mRNA expression of PPARGC1A, IL6, and SRGN was determined by RT-PCR and presented relative to the expression of
RPLP0 and the control (DMSO). Expressed as mean of fold change. *P < 0.05, **P < 0.01, significant difference from control in myoblasts.
§P < 0.05, §§P < 0.01, significant difference from control in myotubes. Error bars represent SEM. All experiments were performed with cells
from three to four different donors.
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Figure 7. A potential role for serglycin in the regulation of serpin E1. The expression of SRGN was knocked down by incubating human
primary muscle cells with siRNA. (A) The mRNA expression of SRGN in myotubes, 1, 2, and 3 days after end of incubation with siRNA. (B) Two
days after transfection with siRNA, 24 h conditioned medium from myotubes was examined with SDS-PAGE and autoradiography. The samples
were incubated with or without trypsin (T; lane 3 and 6) or cABC (lane 2 and 5). C-D) Myoblasts were incubated with SRGN siRNA and the
number of cells (C) and protein concentration (D) were measured after 48 h. (E) Expression of SERPINE1 mRNA in muscle biopsies collected
before (Pre), immediately after 45 min of ergometer cycling (70% VO2max) (0
0) and after 2 h rest (2 h) before as well as after 12 weeks of
training. Data are expressed as FPKM. (F–G) The expression of SRGN was knocked down in human myotubes with siRNA and (F) SERPINE1 was
determined with RT-PCR 1, 2, and 3 days after end of transfection. (F) The concentration of SERPINE1 protein in medium conditioned from 48
to 96 h after transfection. Data on mRNA expression are relative to the expression of RPLP0 and are presented as means of fold change. The
experiments were performed 4–5 times (except for B, where n = 2). Bars depict means  SEM. **P < 0.01, ***P < 0.001.
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ance and strength training 20% of all upregulated genes
were ECM related and these encoded proteases, protease
inhibitors, structural components, and proteoglycans. Our
lists of exercise-regulated ECM genes provide the basis for
molecular follow-up studies, which may unravel some of
the beneficial effects of ECM remodeling on health and
skeletal muscle physiology.
The adipose tissue was influenced by the training inter-
vention as fat mass was reduced by 8.2%. Furthermore,
exercise is known to induce modulation of adipose tissue
metabolism and secretory activity (Golbidi and Laher
2014). We monitored gene expression in adipose tissue
and observed that only a few ECM-related genes were up-
or downregulated. We only have biopsies from subcuta-
neous adipose tissue, thus we do not know whether other
adipose tissue depots would exhibit different responses.
Skeletal muscle is a highly adaptable tissue. Adaptation
to physical activity includes regulation of satellite cell
activity, myogenesis and angiogenesis, tissue expansion
and alterations in structural support (Yan et al. 2011;
Egan and Zierath 2013; Blaauw and Reggiani 2014).
Whereas the muscle undergoes hypertrophy in response
to weight-bearing exercise, muscle wasting occurs when
the muscle is less used as evident during extended inactiv-
ity. It is likely that ECM plays a major role in skeletal
muscle adaptation to different physiological stimuli
(Goody et al. 2015) and that ECM restructuring is neces-
sary during muscle growth. Furthermore, ECM restruc-
turing is important for angiogenesis. Degradation of
basement membrane proteins by proteases has been
shown to be necessary for activity-induced angiogenesis
in rats (Haas et al. 2000).
It is surprising how little is known about the ECM in
skeletal muscle. Our data show that a large proportion of
the transcriptional response to physical activity in skeletal
muscle is related to ECM components and enzymes
involved in tissue remodeling. Fibroblasts are considered
to be the major producers of ECM components in the
muscle (Gillies and Lieber 2011), but muscle cells are also
able to produce ECM proteins (Gillies and Lieber 2011;
Norheim et al. 2011). Norheim et al. reported that many
of the proteins secreted from human muscle cells in cul-
ture are related to the ECM and that they are regulated
by strength training (Norheim et al. 2011). Both fibrob-
lasts and muscle cells sense mechanical load during exer-
cise. Mechanotransduction, partially through integrin
receptors, plays a major role in regulating synthesis and
turnover of ECM components (Kjaer 2004; Humphrey
et al. 2014). Physical activity is accompanied by metabolic
changes including improved insulin sensitivity and it is
possible that this also can lead to altered expression of
ECM-related genes. In murine skeletal muscle, insulin
resistance has been associated with increased collagen
content and reduced MMP9 expression (Kang et al.
2011). Furthermore, insulin-resistant human subjects had
an increased collagen content in skeletal muscle (Berria
et al. 2006).
Also other studies have focused on the transcriptional
response in skeletal muscle to physical activity. Timmons
et al. (2005) used a microarray technique to analyze gene
expression in muscle biopsies from 8 volunteers undergo-
ing 6 weeks of endurance training. Gene ontology analysis
revealed that the ECM gene families were most upregu-
lated after training. It is also worth noting that most
pathological conditions, insulin resistance, atrophy and
aging in skeletal muscle are associated with alterations in
the ECM (Lecker et al. 2004; Berria et al. 2006; Gillies
and Lieber 2011; Kragstrup et al. 2011; Wood et al. 2014)
and we suggest that exercise might counteract some of
these pathological changes.
We chose to focus on proteoglycans, which to our
knowledge have not been systematically investigated in
skeletal muscle in relation to exercise. Of all the known
proteoglycans expressed in muscle, more than half were
upregulated after long-term training. DCN was the pro-
teoglycan with the highest mRNA expression level. In our
dataset DCN expression was not significantly changed by
exercise, but it has previously been shown to be secreted
from contracting skeletal muscle cells in vitro and to be
involved in regulation of muscle hypertrophy by inhibi-
tion of atrophic pathways (Kanzleiter et al. 2014). Synde-
cans are transmembrane heparan sulfate proteoglycans
and play a role in cell proliferation and fusion of satellite
cells into differentiated myotubes (Brandan and Gutierrez
2013b). Both syndecan-3 and 4 are exclusively expressed
in satellite cells in the muscle (Cornelison et al. 2001). In
this study, we show that SDC4 was upregulated after
acute exercise, whereas syndecan-3 was upregulated after
long-term exercise.
Serglycin has previously been regarded as a hemato-
poietic proteoglycan, but has also been identified in
endothelial cells (Schick et al. 2001), chondrocytes (Zhang
et al. 2010), adipocytes (Imoto-Tsubakimoto et al. 2013),
and smooth muscle cells (Lemire et al. 2007). To our
knowledge SRGN has not been studied in skeletal muscle
before. Our data show that SRGN mRNA and protein are
expressed in human muscle biopsies and cultured human
muscle cells. In muscle biopsies, SRGN mRNA was upreg-
ulated after 45 min bicycling and after 12 weeks of com-
bined endurance and strength training.
Electric pulse stimulation was used as an in vitro model
of muscle contraction. When cultured muscle cells were
activated with EPS, SRGN mRNA expression increased.
However, SRGN expression was unaffected by pharmaco-
logical compounds increasing calcium and cAMP signal-
ing, suggesting that the transcriptional regulation of
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SRGN is transmitted through other exercise-responsive
signaling pathways. Furthermore, it has previously been
shown that LPS and interleukin 1b signaling can induce
synthesis and secretion of SRGN in hematopoietic (Kol-
seth et al. 2015) and endothelial cells (Reine et al. 2014).
Here, we show that signaling pathways linked to LPS
stimulation can be involved in regulation of SRGN
expression in human muscle cells.
The functional role of SRGN in muscle cells remains
unknown. Several of the documented functions of SRGN
in other cell types are mediated through regulation of
partner molecules with defined biological activities. SRGN
is important for the formation of storage granules in mast
cells, T lymphocytes and neutrophils where it participates
in storage of several proteases (Abrink et al. 2004; Grujic
et al. 2005; Niemann et al. 2007; Kolset and Pejler 2011;
Wernersson and Pejler 2014) and has a role in secretion
of matrix metalloproteinase-9 and urokinase in macro-
phages (Winberg et al. 2000; Pejler et al. 2003). SRGN
also plays a role in storage of other secreted factors such
as cytokines and growth factors (Kolset and Pejler 2011),
including tumor necrosis factor a (Zernichow et al.
2006), chemokine (C-X-C motif) ligand 1 (CXCL1)
(Meen et al. 2011), and interleukin 13 (Waern et al.
2012).
We speculate that the function of SRGN in muscle cells
is similar to that in other cell types; to interact with
secreted factors and regulate storage or secretion. The fact
that SRGN is a predicted functional partner of SERPINE1
in the STRING database (Korpetinou et al. 2014; Szklar-
czyk et al. 2015) prompted us to investigate this relation
in cultured muscle cells. We show that SRGN knockdown
led to increased SERPINE1 expression and secretion. It
remains to be investigated whether SRGN interacts with
SERPINE1 and has a direct role in its regulation. Skeletal
muscle is now considered an active endocrine organ that
releases myokines, especially during physical activity (Eck-
ardt et al. 2014; Catoire and Kersten 2015). Future studies
will show whether other secreted factors in skeletal muscle
cells are regulated by SRGN.
In addition to highlighting the importance of proteo-
glycans and ECM molecules, we hypothesize that SRGN is
a molecule involved in storage and secretion of secreted
factors in skeletal muscle and thereby involved in the
adaptation of skeletal muscle due to physical activity.
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